Pieris Pharmaceuticals' Merger Target Palvella Doses First Patient in Phase 3 Trial of Lymphatic Drug

MT Newswires00:48

Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN Rapamycin) for the Treatment of Microcystic Lymphatic Malformations

GlobeNewswire11/07 21:30

Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

GlobeNewswire10/17 19:30

Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference

GlobeNewswire10/15 19:30

Pieris Pharmaceuticals' Merger Partner Palvella Therapeutics Receives FDA Office Of Orphan Products Development Grant Of Up To $2.6M For Phase 3 SELVA Trial of QTORIN 3.9% Rapamycin Anhydrous Gel For Microcystic Lymphatic Malformations

Benzinga10/03 19:42

Palvella Therapeutics Awarded Up to $2.6 Million Grant From the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations

GlobeNewswire10/03 19:30